Literature DB >> 20688248

Clinical manifestations and treatment of Churg-Strauss syndrome.

Chiara Baldini1, Rosaria Talarico, Alessandra Della Rossa, Stefano Bombardieri.   

Abstract

Churg-Strauss syndrome (CSS) is a systemic necrotizing vasculitis affecting small to medium-sized vessels, and characterized by asthma, blood hypereosinophilia, and eosinophil-rich granulomatous inflammation of the respiratory tract. In the past few years the pathogenesis of the disease and its clinical manifestations have been clarified, fostering important advances in the treatment of CSS. Systemic corticosteroids are still considered the cornerstone of treatment. Many issues need to be addressed, such as how to maintain remission, prevent disease relapses, and treat refractory disease. This review provides a clinical overview of CSS and a summary of the current treatments and novel therapies. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688248     DOI: 10.1016/j.rdc.2010.05.003

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  25 in total

Review 1.  Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.

Authors:  Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Journal:  Curr Allergy Asthma Rep       Date:  2012-10       Impact factor: 4.806

Review 2.  Non-infectious orbital vasculitides.

Authors:  B Perumal; E H Black; F Levin; J J Servat
Journal:  Eye (Lond)       Date:  2012-02-24       Impact factor: 3.775

Review 3.  Churg-strauss syndrome: an update.

Authors:  Andy Abril
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

4.  DRESS with delayed onset acute interstitial nephritis and profound refractory eosinophilia secondary to Vancomycin.

Authors:  Paloma O'Meara; Rozita Borici-Mazi; A Ross Morton; Anne K Ellis
Journal:  Allergy Asthma Clin Immunol       Date:  2011-10-03       Impact factor: 3.406

Review 5.  Mepolizumab in eosinophilic disorders.

Authors:  J Pablo Abonia; Philip E Putnam
Journal:  Expert Rev Clin Immunol       Date:  2011-07       Impact factor: 4.473

6.  Coronary artery vasospasm and cardiogenic shock as the initial presentation for eosinophilic granulomatosis with polyangiitis.

Authors:  Abdallah Y Bitar; Caleb D Thompson; Christina W Tan; Kavitta Allem; Aelita Khachatrian; Peter J Weis; Vikram Garg; Ajay Srivastava
Journal:  J Cardiol Cases       Date:  2015-12-29

7.  Eosinophilic granulomatosis with polyangiitis in a Nigerian woman.

Authors:  Ngozi Lina Ekeigwe; Olufemi Adelowo; Ehiaghe Lonia Anaba; Hakeem Olaosebikan
Journal:  BMJ Case Rep       Date:  2019-06-18

8.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

Review 9.  Eosinophilic granulomatosis with polyangiitis complicated by cholecystitis: a case report and review of the literature.

Authors:  Lu Ye; Xiaoyong Lu; Jing Xue
Journal:  Clin Rheumatol       Date:  2014-02-11       Impact factor: 2.980

Review 10.  Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Authors:  David Aguirre-Valencia; Iván Posso-Osorio; Juan-Carlos Bravo; Fabio Bonilla-Abadía; Gabriel J Tobón; Carlos A Cañas
Journal:  Clin Rheumatol       Date:  2017-07-31       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.